SIBP A17
Alternative Names: SIBP-A-17Latest Information Update: 20 Sep 2024
At a glance
- Originator Shanghai Institutes for Biological Sciences
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Jul 2024 Preclinical trials in Solid tumours in China (IV) prior to July 2024 (IV) (NCT06512116)
- 22 Jul 2024 Shanghai Institute Of Biological Products plans to initiate a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Unresectable/ Inoperable, Second-line therapy or greater) in July 2024 (NCT06512116)